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Abstract
The direct C–H functionalization methodology has first been applied to perform transition metal-free C–H/C–Li cross-couplings of
2H-imidazole 1-oxides with carboranyllithium. This atom- and step-economical approach, based on one-pot reactions of nucleo-
philic substitution of hydrogen (SNH) in non-aromatic azaheterocycles, affords novel imidazolyl-modified carboranes of two types
(N-oxides and their deoxygenative analogues), which are particularly of interest in the design of advanced materials.
Introduction
Dicarbadodecaboranes (carboranes) are known to be 3D poly-
hedral clusters with a special type of structural organization,
relative thermal and chemical stabilities, as well as unique phys-
icochemical properties [1-3]. The functional derivatives of
carboranes, in particular heterocyclic ones, are undeniably of in-
creased interest in the chemistry of organoboron compounds
due to wide opportunities to use these boron-enriched
substances as diagnostic tools for tumor radio imaging [4-7],
promising agents for boron neutron capture therapy (BNCT) of
cancer [8-12], as well as agonists and antagonists of biological
receptors [13-17], etc. In addition, azaheterocyclic carboranes
are actively used as ligands in the synthesis of metal complexes
of various architectures, possessing catalytic activity [18-21], as
well as unique photophysical properties [22-26]. Thus, the de-
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velopment of effective approaches to azaheterocyclic carbo-
ranes is currently considered to be one of the most important
synthetic challenges.
At present, there are three main synthetic strategies in the
design of promising heterocyclic carboranes: (i) condensation
of decaborane (B10H14) with substituted acetylenes [27-30],
(ii) carboryne-based cycloaddition reactions [31-33], and
(iii) C–X/C–M cross coupling of halogenated azaheterocycles
(X = Br, Cl, F) with carborane organometallic derivatives
(M = Li, Cu) [11,22,34,35]. Despite the fact that the latter syn-
thetic strategy is in common use, it has significant limitations.
In particular, the preliminary functionalization of heterocyclic
substrates is required to apply this cross-coupling methodology.
Thus, the development of pot-, atom- and stage-economical
(PASE) [36-38] methods leading to novel C-modified ortho-
carboranes, as well as elucidation of scope and mechanistic fea-
tures of these transformations, is one of the crucial steps to
obtain promising boron-enriched heterocyclic ensembles and
functional materials based on them. An alternative approach to
exploit the C–X/C–M cross-coupling reactions, leading to
heterocyclic boron clusters, is based on the C–H/C–M coupling
strategy. One of the ways to realize these cross couplings is the
transition metal-free methodology for direct C–H functionaliza-
tion of azaheterocyclic substrates [39-42], which can be carried
out by using SNH reactions (nucleophilic substitution of hydro-
gen) [43-48]. The SNH methodology corresponds to the basic
principles of green chemistry [49-53], and it is now considered
to be one of the most valuable approaches to functionally
substituted azaheterocycles, since these transformations can be
performed without any catalysis by transition metals, neither
they need preliminary introduction of good leaving groups into
heterocyclic substrates.
It is known that SNH reactions have successfully been applied in
the chemistry of π-deficient (hetero)aromatic systems as an
effective and useful synthetic approach [43-48]. These transfor-
mations have been used for the synthesis of various mono-, di-,
and triazinyl-modified carboranes [54-56]. At the same time, a
limited number of protocols describe application of SNH reac-
tions to functionalize non-aromatic heterocycles. In particular,
only few examples of SNH reactions are available in the chem-
istry of 2H-imidazole 1-oxides [57-60] that are of interest
as promising pharmacoactive azaheterocyclic compounds
[61-65].
In this paper, we wish to report the first examples of the
SNH methodology for the synthesis of new heterocyclic carbo-
ranes by means of direct C–H/C–Li coupling of non-aromatic
2H-imidazole 1-oxides with carboranyllithium. A growing
interest in bifunctional compounds, bearing both the pharma-
coactive imidazole motif and a polyhedral boron-enriched scaf-
fold, is likely to be due to unique properties of these organo-
boron compounds and materials based on them.
Results and Discussion
2H-Imidazole 1-oxides are known to be non-aromatic hetero-
cyclic compounds, bearing the electrophilic center C(5)–H,
which is active for interaction with nucleophilic reagents. This
feature enables one to carry out the direct nucleophilic functio-
nalization of the C(sp2)–H bond, thus leading to novel C(5)-
modified 2H-imidazoles. We have established that carboranyl-
lithium, generated in situ from 1,2-dicarba-closo-dodecaborane
[66], can be involved in the above mentioned C–H/C–Li cou-
pling reactions successfully as a nucleophilic partner.
The direct transition metal-free C–H/C–Li cross-coupling reac-
tions of 2H-imidazole 1-oxides 1a–d with 2 have been found to
result in the novel carboranes 4a–d and 5a–d of various archi-
tectures. These transformations are able to be considered as
nucleophilic substitution of hydrogen (SNH) in non-aromatic
N-oxides of 2H-imidazoles 1a–d. It has also been shown that
the SNH reactions can be realized via either an "addition–elimi-
nation" SNH(AE) mechanism, or through an "addition–oxida-
tion" SNH(AO) scheme to form imidazolyl carbonanes 4a–d and
5a–d, respectively.
In accordance with the current SNH concept, the first step of
both protocols, SNH(AE) and SNH(AO), involves a reversible
formation of unstable anionic σH-adducts 3(a–d)-OLi as a
result of nucleophilic attack of carboranyllithium 2 at the
CH=N+–O− bond of 2H-imidazole 1-oxides 1a–d. The second
step can be carried out in both eliminative and oxidative
versions, the structure of the final carboranylated 2H-imida-
zoles 4a–d and 5a–d being controlled by the reaction condi-
tions used.
In order to accomplish the nucleophilic substitution of hydro-
gen according to the "addition–elimination" scheme SNH(AE),
the key factor has been shown to be the presence of a deoxy-
genating reagent in the reaction mixtures, containing the
σH-adducts 3(a–d)-OLi. Indeed, it has been found that addition
of acylating agents to intermediates 3(a–d)-OLi facilitates elim-
ination of hydrogen from the σH-adducts along with the
oxygen-containing fragment from the N+–O− moiety to form
imidazolyl-substituted carboranes 4a–d with the loss of the
N-oxide function (Scheme 1).
In order to find out the optimal reaction conditions for the
SNH(AE) pathway, affording the maximum yields of the target
products 4, the effects of various factors (type of acylating
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Scheme 1: C–H/C–Li cross-coupling reactions of 2H-imidazole 1-oxides 1a–d and carboranyl lithium 2. The reactions were carried out in accordance
with the optimized coupling conditions according to the "addition–elimination" SNH(AE) or "addition–oxidation" SNH(AO) pathways (Table 1 and
Table 2).
agents, exposure time for which the reaction mass is kept after
mixing 2H-imidazole N-oxide 1 with carboranyllithium 2 and
quenching with an acylating agent, as well as the temperature
regime, at which the deoxygenative agent is added) have been
studied. The cross-coupling reaction of 2,2-dimethyl-4-phenyl-
2H-imidazole 1-oxide (1a) with carboranyllithium 2 was chosen
as a model reaction. It has finally been found that the best yield
of 4a is achieved using AcCl as a deoxygenative agent
at room temperature with stirring of the resulted reaction mix-
ture for 15 min (Table 1, entry 11). Thus, a number of novel
heterocyclic carboranes 4a–d have been synthesized in
40–55% yields following the optimized reaction conditions
(Scheme 1).
In case of the "addition–oxidation" protocol realization for the
SNH (AO) reactions, an oxidative agent to convert the
σH-adducts 3(a–d)-OLi into the corresponding imidazolyl
carboranes 5a–d with retention of the N-oxide function in the
imidazole moiety, has been found to play a key role. It should
be noted that optimization of the reaction conditions for oxida-
tive C–C couplings has been carried out by using the model
reaction of 2,2-dimethyl-4-phenyl-2H-imidazole 1-oxide (1a)
with carboranyllithium 2. The experiments performed have
shown effects of the used oxidants, temperature regime, and
exposure time after addition of an oxidant into the reaction mix-
ture. As a result, the optimal conditions have been found to
involve the use of DDQ as oxidant and refluxing of the reaction
mixture in argon atmosphere for 1 h (Table 2, entry 12). It has
also been observed that further increase in the exposure time
does not improve yields (39–52%) of the target carboranyl-
substituted imidazole 1-oxides 5a–d (Scheme 1). Besides com-
pounds 5a–d, the formation of their deoxygenated analogues
4a–d has been shown to take place in trace amounts under the
optimized reaction conditions. The latter are supposed to be
derived from elimination of hydrogen and the oxygen-contain-
ing moiety from the corresponding σH-adducts.
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Table 1: Optimization of the reaction conditions for the C–H/C–Li cross-coupling of 2H-imidazole 1-oxides 1a–d with carboranyllithium 2 according to
the "addition–elimination" protocola.
entry temperature, °Cb exposure time (min)c acylating agent yield of 4a (%)
1 −78 15 Ac2O 9
2 −78 30 Ac2O 9
3 0 15 Ac2O 17
4 0 30 Ac2O 17
5 rt 15 Ac2O 28
6 rt 30 Ac2O 27
7 −78 15 AcCl 12
8 −78 30 AcCl 12
9 0 15 AcCl 23
10 0 30 AcCl 23
11 rt 15 AcCl 43
12 rt 30 AcCl 40
13 −78 15 TFAA 7
14 −78 30 TFAA 7
15 0 15 TFAA 14
16 0 30 TFAA 14
17 rt 15 TFAA 18
18 rt 30 TFAA 18
aThe reaction was carried out in dry THF using 2H-imidazole 1-oxide 1a (1.1 equiv), carboranyllithium 2 prepared from o-carborane (1.0 equiv) and
n-BuLi (1.1 equiv) at −78 °C. bThe temperature at which the acylating agent was added. cBetween addition of 2H-imidazole 1-oxide 1a to carboranyl-
lithium 2 and quenching with the acylating agent.
Table 2: Optimization of the reaction conditions for the C–H/C–Li cross-coupling of 2H-imidazole 1-oxides 1a–d with carboranyllithium 2 according to
the "addition–oxidation" protocola.
entry oxidant temperature, °Cb exposure time (min)c yield of 5a (%)
1 – Rt 30 trace
2 – Rt 60 trace
3 – 40 30 5
4 – 40 60 7
5 – reflux 30 9
6 – reflux 60 12
7 DDQ Rt 30 7
8 DDQ Rt 60 7
9 DDQ 40 30 9
10 DDQ 40 60 11
11 DDQ reflux 30 35d
12 DDQ reflux 60 42d
13 DDQ reflux 120 42d
14 p-chloranyl rt 60 5
15 p-chloranyl 40 60 7
16 p-chloranyl reflux 30 17
17 p-chloranyl reflux 60 31
18 p-chloranyl reflux 120 30
aThe reaction was carried out in dry THF using 2H-imidazole 1-oxide 1a (1.1 equiv), carboranyllithium 2 prepared from o-carborane (1.0 equiv) and
n-BuLi (1.1 equiv) at −78 °C. bThe temperature at which the reaction mixture was stirred after addition of oxidant. cExposure time after addition of
oxidant to the reaction mixture. dImidazolyl carborane 4a was isolated in trace amounts.
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Figure 1: The 1H NMR spectra of 1-(5-(4-bromophenyl)-2-ethyl-2-methyl-2H-imidazol-4-yl)-1,2-dicarba-closo-dodecaborane (4d) and 1-(4-(4-bromo-
phenyl)-2-ethyl-2-methyl-1-oxido-2H-imidazol-5-yl)-1,2-dicarba-closo-dodecaborane (5d) in CDCl3 at 295 K.
It is worth mentioning that the C–H/C–Li coupling reactions of
2H-imidazole 1-oxides 1c,d with carboranyllithium 2 have been
found to result in the formation of p-bromophenyl derivatives
4c,d and 5c,d, which are of particular interest as valuable
synthons for further modifications, for instance by means of
transition metal-catalyzed C–Br/C–M (M = Li, Mg, Zn, etc.)
and C–Br/C–H cross-couplings reactions leading to more com-
plex organic compounds.
Mono-substituted imidazolyl carboranes 4a–d and their N-oxide
analogues 5a–d were characterized by the data of elemental
analysis, IR, NMR spectroscopy (1H, 13C{1H} (APT), 11B,
11B{1H} experiments), and mass spectrometry. In the IR spec-
tra of 4a–d and 5a–d, there are absorption bands corresponding
to the stretching vibrations of carborane B–B atoms
(ν 713–721 cm−1), B–H (ν 2561–2605 cm−1) and C–H
(ν 3026–3075 cm−1). In the 1H NMR spectra of 4a–d and 5a–d
the resonance signals of both carborane and imidazole frag-
ments were observed. Typical 1H NMR spectra of carboranyl-
substituted imidazoles and their N-oxides (4d versus 5d) are
shown in Figure 1. In these spectra, the characteristic signals of
C-substituted carborane are registered as two sets, correspond-
ing to CCarb–H and B–H protons. The chemical shift of unsub-
stituted carborane Ccarb–H proton resonance has been shown to
depend on the presence of the N+–O– moiety in the imidazole
ring. In particular, a broadened singlet of the Ccarb–H proton is
exhibited at δ 4.63–4.58 ppm in the 1H NMR spectra of 4a–d,
while in the spectra of their N-oxide analogues 5a–d the corre-
sponding singlet is observed at δ 6.09–6.03 ppm. Such differ-
ence in chemical shifts is likely to be due to the effect of the
imidazole N+–O– group oxygen. Carborane B–H protons are
observed as 10 H broadened multiplets at δ 3.08–1.61 ppm. The
proton resonances of C(2)-alkyl and C(4)-aryl substituents are
observed in the appropriate fields: at δ 2.17–0.61 ppm and
δ 7.67–7.22 ppm, respectively.
In the 13C NMR spectra, one can also see the difference in
chemical shifts for carbon-13 resonance signals of imidazoles
4a–d and their N-oxide analogues 5a–d. Indeed, in the
13C NMR spectra of 4a–d the carbon-13 resonances of
organoboronic  Cc a r b–H fragments  are  observed at
δ 61.75–61.47 ppm, while in the spectra of their N-oxides 5a–d
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Figure 2: Fragment of the 2D 1H–13C{1H} HSQC (a) and HMBC (b) spectra of imidazolyl carborane 5d in CDCl3 at 295 K (the whole spectra are
shown in Supporting Information File 1).
the corresponding signals are exhibited at δ 57.64–57.63 ppm.
The carbon resonances associated with the imidazole ring have
been recorded at δ 69.36–69.12 ppm and at δ 65.66–65.41 ppm
in the 13C NMR spectra of compounds 4a–d and 5a–d, respec-
tively. In the mass spectra of carboranylimidazoles the corre-
sponding molecular ion [M]+ peaks have also been registered. It
should be mentioned that [M]+ values, observed for the N-oxide
series of compounds 5a–d, proved to differ from those regis-
tered for the deoxygenated analogues 4a–d by atomic oxygen
mass (16 amu).
The novel imidazolyl carboranes 4a–d and 5a–d obtained are
considered to be complex closo-cluster structures formed by
polyboron and heterocyclic scaffolds linked to each other
through the C–C bond. In order to correlate the resonance
signals with the assumed structure unambiguously, two-dimen-
sional NMR correlation 1H–13C spectra, showing direct
(HSQC) and distant (HMBC) spin–spin constants, have been re-
corded for compound 5d (Figure 2). The presence of the cross-
peak {6.09, 57.64} in the HSQC spectrum of 5d and absence of
any signals in these regions in the HMBC spectrum enables one
to state that these signals belong to proton (δ 6.09 ppm) and car-
bon (δ 57.64 ppm) resonances of the CCarb–H fragment. Also,
the 2D spectra allow one to distinguish the carbon resonances of
2H-imidazole methyl (δ 24.06 ppm) and ethyl (δ 6.74 and
31.12 ppm) groups. In addition, the interaction observed in the
HMBC spectra of quaternary carbons with protons of methyl
and ethyl groups through the long-range constants allows the
signal at δ 103.85 ppm in the 13C NMR spectra of 5d to be attri-
buted to C-2 of the imidazole ring.
The structure of imidazolyl carborane 5d has also been proved
by the X-ray analysis (Figure 3). The single crystals were ob-
tained by slow evaporation of imidazolyl carborane 5d from a
mixture of CH2Cl2/heptane, 8:2. According to the XRD data,
two independent molecules have been found to be crystallized
in the P1211 chiral space group of the monoclinic system.
General views for molecules 1 and 2 are shown in Figure 3,
atoms of the molecule 2 being labeled with the additional index
“A”. Both independent molecules proved to be characterized by
the (R)-configuration of the C(2)-chiral center and the appro-
priate bond and angle distances. Both heterocyclic rings have
been found to be planar with 4-BrC6H4 substituent being turned
towards the heterocyclic fragments, thus forming the angles of
74° and 80°, respectively. In the crystals of molecule 1, the
2H-imidazole 1-oxide fragment is disordered into two positions
with occupancy coefficient of 0.8/0.2. The minor disordered
moiety has been confirmed to be in the (S)-configuration. Also
it is worth mentioning that no shortened contacts have been ob-
served in the crystals.
Conclusion
The direct C(sp2)–H functionalization methodology has first
been applied to design the synthesis of polyhedral boron closo-
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Figure 3: Molecular structure of 5d. Selected bond distances (Å) and angles (deg) for molecule 1: C(3)–C(14), 1.665; C(3)–C(5), 1.491; C(5)–N(1),
1.338; C(5)–C(4), 1.472; Br(1)–C(9), 1.910; O(1)–N(1), 1.281; N(3)–C(4), 1.30; N(3)–C(2), 1.45; C(2)–C(1), 1.54; C(2)–C(12), 1.53; C(6)–C(4), 1.499;
C(4)–N(3)–C(2), 108.2; O(1)–N(1)–C(2), 120.3; O(1)–N(1)–C(5), 130.0; C(5)–C(3)–C(14), 116.6; C(12)–C(2)–N(1), 108.4; C(1)–C(2)–N(3), 111.4;
C(1)–C(2)–C(12), 113.8; for molecule 2 “A”: C(3A)–C(15), 1.65; C(3A)–C(5A), 1.500; C(5A)–N(1A), 1.326; C(5A)–C(4A), 1.468; Br(2)–C(9A), 1.904;
O(1A)–N(1A), 1.267; N(3A)–C(4A), 1.300; N(3A)–C(2A), 1.441; C(2A)–C(1A), 1.523; C(2A)–C(12A), 1.532; C(6A)–C(4A), 1.491; C(4A)–N(3A)–C(2A),
108.6; O(1A)–N(1A)–C(2A), 120.4; O(1A)–N(1A)–C(5A), 130.4; C(5A)–C(3A)–C(15), 116.5; C(12A)–C(2A)–N(1A), 107.1; C(1A)–C(2A)–N(3A), 113.0;
C(1A)–C(2A)–C(12A), 112.0.
clusters. Novel heterocyclic carboranes have been obtained
through a one pot-, atom- and stage-economical approach,
based on nucleophilic substitution of hydrogen (SNH) in
2H-imidazole 1-oxides by action of carboranyllithium, gener-
ated in situ from commercially available o-carborane. It has also
been found that the SNH(AE, «addition–elimination») scheme
leads to carboranyl-substituted 2H-imidazoles, while alterna-
tive SNH(AO, «addition–oxidation») results in the correspond-
ing N-oxide analogues. In summary, novel organoelement
bifunctional ensembles, bearing heterocyclic and carborane
moieties, which are of particular interest in the design of ad-
vanced materials, have been obtained in good yields.
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